Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Brea
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| PUMA BIOTECHNOLOGY, Inc. (NASDAQ: PBYI) | Delayed: 11.26 +0.36 (3.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.90 | 52 Week High | $82.81 | |||
| Open | $10.93 | 52 Week Low | $19.74 | |||
| Day High | $11.38 | P/E | N/A | |||
| Day Low | $10.92 | EPS | $-2.16 | |||
| Volume | 395,525 | |||||
